Navigation Links
New Phase 3 Study of Tapentadol Immediate Release Tablets Published in Current Medical Research and Opinion Journal
Date:5/26/2009

Data Confirm Tapentadol Efficacy and Tolerability for Acute Pain Patients

RARITAN, N.J., May 26 /PRNewswire-USNewswire/ -- It is estimated that up to 30 percent of all people who have surgery experience gastrointestinal side effects, such as nausea and vomiting. The use of opioid pain medicines during and after surgery is a leading risk factor for experiencing these side effects. Nausea and vomiting are uncomfortable and bothersome and can have an impact on a patient's recovery.

According to a new Phase 3 clinical study published in the June 2009 issue of Current Medical Research and Opinion, and in an online version of the journal, tapentadol immediate release (IR) tablets provided patients with equivalent efficacy in pain relief following orthopedic surgery and significant reduction in nausea and/or vomiting compared to oxycodone IR.

Results from the new Phase 3 study of tapentadol IR tablets, a prescription oral analgesic approved by the U.S. Food and Drug Administration (FDA) in November 2008, showed that patients receiving 50-mg or 75-mg of the medication experienced significant relief of moderate to severe acute pain after a bunionectomy, one of the most common foot surgeries, compared with placebo. Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD), Raritan, NJ, and Grunenthal GmbH, Aachen, Germany, supported this study.

The overall difference in the intensity of pain experienced by patients recovering from bunionectomy was examined during the first 12, 24, 48 and 72 hours after initiating treatment with tapentadol IR. Both tapentadol IR treatment groups showed a statistically significant improvement in pain compared to patients who received placebo, during all of these time periods (P <0.001), achieving both the primary efficacy endpoint of the sum of pain intensity difference (SPID) at 48 hours and secondary efficacy endpoints (SPID(12),
'/>"/>

SOURCE Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Dainippon Sumitomo Pharma Announces Lurasidone Phase III Data in Patients With Schizophrenia
2. Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS)
3. Essentialis Meets Primary Endpoint in Phase 2b Trial of DCCR for Treatment of Hypertriglyceridemia and is Granted Extensive Patent Coverage in the US
4. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
5. BioVex to Report Phase I/II Clinical Trial Results for the Front Line Treatment of Head and Neck Cancer With OncoVEX GM-CSF at the 2009 American Society of Clinical Oncology Meeting
6. Novavax Completes Enrollment of Its Second Phase II Seasonal Influenza VLP Vaccine Clinical Trial
7. Pixantrone Phase 3 Data to be Presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting
8. Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009
9. Metabolic Solutions Development Company Announces Preliminary Results from Phase IIa Clinical Trial
10. Medarex Announces Primary Endpoint Achieved in MDX-1100 Anti-IP-10 Antibody Phase 2 Trial for Rheumatoid Arthritis
11. Circassia Begins Phase II Clinical Trial With Ragweed Allergy Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... 21, 2014  The University of Maryland,s A. James ... groundbreaking of the new A. James Clark Hall at ... will cultivate transformative new engineering and biomedical technologies to ... at 10:00 a.m. on November 21 at the site ... Lot, adjacent to the Jeong H. Kim Engineering Building, ...
(Date:11/21/2014)... SARASOTA, Fla. , Nov. 21, 2014   ... ) announced that the Company is scheduled to present ... San Francisco, CA on January 12-14, ... PhD, Chairman and CEO of Rock Creek Pharmaceuticals, will ... small molecule cholinergic agonist which exhibits anti-inflammatory pharmacological characteristics. ...
(Date:11/21/2014)... PLAINFIELD, N.J. , Nov. 21, 2014  PTC Therapeutics, ... that the 2014 Legend of Technology Award for Vision, Innovation, ... , Ph.D., Chief Executive Officer. This award recognizes an individual ... in New Jersey for several decades. ... of Technology Award," stated Stuart Peltz , Ph.D., CEO ...
Breaking Medicine Technology:University of Maryland Breaks Ground for A. James Clark Hall 2University of Maryland Breaks Ground for A. James Clark Hall 3University of Maryland Breaks Ground for A. James Clark Hall 4Rock Creek Pharmaceuticals to Present at the Biotech Showcase 2015 2Rock Creek Pharmaceuticals to Present at the Biotech Showcase 2015 3Rock Creek Pharmaceuticals to Present at the Biotech Showcase 2015 4PTC Therapeutics Announces CEO, Dr. Stuart Peltz Recipient of The New Jersey Technology Council's 2014 Legend of Technology Award 2PTC Therapeutics Announces CEO, Dr. Stuart Peltz Recipient of The New Jersey Technology Council's 2014 Legend of Technology Award 3
(Date:11/23/2014)... November 23, 2014 Locks-Magnetic.com, a notable ... doors. Moreover, all the new products are available at ... marketing manager is proud of the new emergency doors. ... automatically. And customers can choose from several colors. All ... high quality emergency door release is not as easy ...
(Date:11/23/2014)... More than two dozen new claims were ... involving Byetta lawsuits ( http://www.byettalawsuit2013.com/ ), as well as ... , A Case List updated on November 17th ... 2 diabetes medications referred to as incretin mimetics have ... District of California, where a federal proceeding continues to ...
(Date:11/23/2014)... 23, 2014 The FDA is Watching: ... **FDAnews On-Demand Webinar**, Dec. 11, 2014 ? Any Time ... FDA’s focus on promotional activities is no longer limited ... they're looking at websites, Twitter, journal articles, TV appearances, ... Thursday, Dec. 11, for On-Demand access to Timothy Ayers ...
(Date:11/23/2014)... 2014 Today Zane Benefits, the ... businesses, announced their new on demand webinar which ... Health Insurance. , According to Zane ... risk facing most American families. It is also ... large, when it comes to recruiting and retaining ...
(Date:11/22/2014)... PrettyTailor , an outstanding dress company, has recently updated ... buy new dresses at its online shop now. For ... As a matter of fact, PrettyTailor specializes in beautiful ... types of wedding outfits, including bridesmaid dresses, mother of ... provides a variety of occasion dresses, such as cocktail ...
Breaking Medicine News(10 mins):Health News:California Federal Court Overseeing Byetta Lawsuits, Other Incretin Mimetic Claims Adds New Cases in November, Bernstein Liebhard LLP Reports 2Health News:California Federal Court Overseeing Byetta Lawsuits, Other Incretin Mimetic Claims Adds New Cases in November, Bernstein Liebhard LLP Reports 3Health News:California Federal Court Overseeing Byetta Lawsuits, Other Incretin Mimetic Claims Adds New Cases in November, Bernstein Liebhard LLP Reports 4Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 2Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 3Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 4Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 5Health News:Zane Benefits, Inc. Announces New Webinar on The End of Employer-Provided Health Insurance Now Available On-Demand! 2Health News:Customers Are Welcome to Shop at PrettyTailor.com 2
... State University biologist continue to collaborate with the Harvard ... of a certain cellular process that can play a ... K-State associate professor in the Division of Biology, received ... Institute of General Medical Sciences through Recovery Act funding. ...
... 21 One in eight women will be diagnosed with breast cancer ... common type of cancer among women in the United States. Early detection ... one diagnosis is 98 percent. Stage two still has a very high ... the story here: http://www.mediaseed.tv/Story.aspx?story=37000 , , ...
... LONDON, Sept. 21 /PRNewswire-FirstCall/ - Equity Capital ... a preliminary review of the HTDS business ... to all HTDS followers at the following ... Management PLC, (ECM) believes that in the ...
... , KANSAS CITY, Mo., Sept. 21 Public ... recommend seasonal influenza vaccination as the first line of defense this ... The American Lung Association of the Central States is kicking ... City and is supporting local public health efforts to get Greater ...
... , , BEDFORD, Mass., Sept. ... their "Passion & Results" Award. The winners were presented with ... International Society on Thrombosis and Haemostasis (ISTH) held in Boston, MA, ... for Clinical Chemistry (AACC), in Chicago, IL, July 19-23. ...
... from dementia , MONDAY, Sept. 21 (HealthDay News) -- ... pace, and by next year 35.6 million people around the ... since 2005, a new report predicts. , Incidence of ... in 2030 and 115.4 million in 2050, according to ...
Cached Medicine News:Health News:Equity Capital Management H1N1 Vaccines and Hard to Treat Diseases (HTDS) 2Health News:The American Lung Association of the Central States Encourages Greater Kansas City Metro Residents to See Themselves Among the Many 'Faces' of Influenza 2Health News:The American Lung Association of the Central States Encourages Greater Kansas City Metro Residents to See Themselves Among the Many 'Faces' of Influenza 3Health News:The American Lung Association of the Central States Encourages Greater Kansas City Metro Residents to See Themselves Among the Many 'Faces' of Influenza 4Health News:The American Lung Association of the Central States Encourages Greater Kansas City Metro Residents to See Themselves Among the Many 'Faces' of Influenza 5Health News:Instrumentation Laboratory Announces 'Passion & Results' Award Winners 2Health News:Instrumentation Laboratory Announces 'Passion & Results' Award Winners 3Health News:Instrumentation Laboratory Announces 'Passion & Results' Award Winners 4Health News:Alzheimer's Soars, Global Focus Needed: Study 2Health News:Alzheimer's Soars, Global Focus Needed: Study 3
Soft yet durable, these single-patient use pads are designed to have the quality look of reusable pads but provide the hygienic advantages of disposability....
The lower body blanket is designed to be used primarily during surgery on the upper half of the body....
Cocoon Disposable Patient Warming Blankets are specially designed to prevent hypothermia and maintain normothermia in your patients. The soft warm coloured material is strong and resists tearing and ...
The fabric is antistatic and non-linting and is both oil and water repellent.These superior blankets are an environmental friendly alternative to disposable blankets....
Medicine Products: